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1. Introduction
Fifty per cent of primary brain tumours are Glioblastoma (GBM), the rest is constituted by
astrocytomas and less aggressive tumours [1,2]. GBM is biologically an aggressive tumor
quickly developing genetic hetereoneity and therapeutic resistance [2,3]. No specific markers
exist for GBM at the moment as reported by Kesari [4], but new imaging techniques including
diffusion weighted imaging (DWI), perfusion weighted imaging (PWI or MR), are aiding in
better defining disease development and progression. According to the World Health Organ‐
ization (WHO), astrocytomas are classified into four prognostic grades [4,5]. Grade I and two
are classified as low grade gliomas whereas grade III and IV are classified as high grade
gliomas, despite the fact that these grades indicate tumor aggressiveness they have not been
reliable in predicting the response to therapy. Kesari has outlined that other factors such as
overexpression of some growth factors and their receptors have prognostic relevance [4].
Overexpression of Platelet derived growth factor (PDGF) and its receptors indicates a tumor
is less aggressive and has a better prognosis compared to GBM expressing the Epidermal
Growth Factor (EGFR) [4,6].
Almost 45% of GBM have molecular alterations of the enzyme 06-methylguanine-DNA
methyltransferase(MGMT) and mutations of isocitrate dehydrogenase 1 (IDH1) [7]. MGMT,
affects signalling pathways and has an important role with alkylating cytostatic drugs such as
Temozolomide (TMZ). Methylation of MGMT is associated to a better prognosis and response
© 2013 Baronzio et al.; licensee InTech. This is an open access article distributed under the terms of the
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to TMZ [8]. More recently, a specific and target therapy has been suggested by authors such
as Reardon and Wen [3] who have provided a complete list of these inhibitors for this disease
including: Gefitinib (Iressa®), Ernolitib (Tarceva®),Thalidomide (Thalidomid®), Bezacizu‐
mab (Avastin®), and proteasome inhibitors (bortezomid).
Another approach at the moment not completely in use is immunotherapy [9, 10]. EGFR is
expressed in near the 50% of patients with GBM [11]. Inhibitors of EGFR, like Iressa and Tarceva
have been used with limited success [12]. A phase II study with Gefitinib has been conducted by
Rich et al. in which fifty-seven patients have been treated orally once daily with 500 mg of oral
Iressa®. No objective responses were seen, possibly because only 21% of patients had measura‐
ble disease at treatment initiation. Iressa® was well tolerated and a dose increase was thus
suggested [13]. Studies with Tarceva® has given similar results with a minimum benefit not
superior to standard treatment of care with radiotherapy and TMZ [14]. Another modest
response has been obtained inhibiting the PDGF receptors using imatinib (Gleevec®) [10, 16].
Lasty, as angiogenesis due tumor hypoxia is a common processes in GBM [17,18], the inhibitor
of Vascular Endothelial Growth Factor (VEGF) bevacizumab (Avastin) has been studied
extensively in treating resistant GBM [17, 19]. Avastin has recently been used as single agent
or in combination with several drugs, such as carboplatin [20], Ectoposide [21], Lomustine and
TMZ [17]. Avastin, is a recombinant monoclonal immunoglobulin able to inhibit VEGF and to
normalize tumor vasculature [21,22], but, the promises on GBM have not been confirmed and
98.8% of patients experienced adverse effects such as fatigue, headache, hypertension,
thromboembolism, cerebral haemorrhage, convulsion and infarction [22]. Another antiangio‐
genetic factor Thalidomide has been used in GBL [23]. Thalidomide exert its anti tumoral
activity through several mechanisms, such as: inhibition of angiogenesis, cytokine-mediated
pathways and adhesion molecules modulation, inhibition of cyclooxygenase-2 and stimula‐
tion of immuno response [24]. Another approach is immunotherapy. As known GBL is an
immunogenic tumor exerting an immunosuppressive effects on cell mediated immunity
partially by regulatory T cells [25,26,27]. This kind of therapy is however experimental and
dependent on laboratory skilled personal.
However, none of these association are really superior to TMZ + radiotherapy, regarding
survival, and are also becoming cost - prohibitive [28]. Understanding this issue we have
started to add hyperthermia (HT) to TMZ and Conformal Radiotherapy (CRT). The basis for
adding HT together radiotherapy have been described since 2006 [29]. Hypoxia, the increased
apoptosis induced by heat and the additive response to CRT are the most important reasons
for adding HT in the treatment of GBM [29]. Animal and human studies have also indicated
that there are significant chemosensitizing effects of adding HT to chemotherapy such as
nitrosureas derivates [29, 30]. Previous studies not yet published by our group have shown
that HT with TMZ is additive. We have thus be (TMZ) (5F,11 M median age 44.64 ± 9.95 yr),
and were eligible to be compared with 15 patients with (GBM) treated with CFRT plus TMZ
(see table 2)( 15 GBM, 7F,8M; 52.13±16.17 yr). Four of them (Astrocytoma IV ) were previous
treated with CCNU, with disease progression (see. Table. 1). All patients had a histological
proven malignant GBM or anaplastic astrocytomas. Since 2001, we have begun to use capac‐
itive HT in association to TMZ and conformal radiotherapy. Follow up of patients was collected
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at a mean interval of 65 days, with a large range [40-90] days for those patients with a disease
stabilization.
PTS Year Gender Histology TMZ CCNU ECOG Gy RTV Ner HT
Cycle
A/D Survival
Ms
1 36 F GBM X 45 65.6 2 D 25
2 52 M GBM X 42 101 1 D 12
3 54 F GBM X 60 1 A 75
4 57 M GBM X 14 42 3 A 51
5 51 M GBM X 20 57 2 A 20
6 45 F GBM X 65 43.4 1 A 20
7 70 M GBM X 28 28.4 5 A 96
8 31 M GBM X 14 64 1 D 7
9 41 F GBM 3 41 64 1 D 12
10 33 M GBM 28 28.4 2 A 83
11 60 F GBM 1 65 64 1 D 12
12 40 F Astro IV X X 10 25 72.5 1 D 9
13 43 M Astro IV X X 2 47.6 33.6 2 D 7
14 59 M Astro IV X X 4 45 32.9 1 A 19
15 37 M Astro IV X 1 42 101 1 D 12
16 45 F Astro IV 1 44 113 1 A 98
17 44 M Astro IV 10 39.6 3 A 82
18 44 M AstroII 10 45 65.6 4 A 111
19 34 M AstroII X 39.6 44 1 D 23
20 44 F AstroII 10 43 112 6 D 17
21 34 M AstroII 45 1 A 76
22 40 F Astro II X 4 D 12
23 30 M Astro II X 6 A 60
24 46 M Astro II X 6 A 30
25 46 M Astro II X 9 A 17
25> 9F- 16M 11GBM, 6
Astro IV, 8
Astro II
39.9±14.
39
62.91±27.
95
13A-12D 39.44±34.2
5
Pts: Patients; GBM: Glioblastomas, Astro: Astrocytomas; RTV: radiotherapeutic volume; Gy: Gray; D: dead, A: Alive; Ms:
months
Table 1. Characteristics of patients with GBM – ASTRO- II- IV treated with CFRT+ HT
1.1. Conformal radiotherapy
Computer  tomographic  (CT)  scans  using  a  spiral  CT  scanner  and  magnetic  resonance
scanner (MR) were performed on each patients. These scans are elaborated for determin‐
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ing the cancer size and shape in 3 dimensions (3D).  In this way precisely focused, high
dose,  radiation  beams  can  be  delivered  to  cancer  mass  in  multiple  treatment  sessions.
Before radiation,  patients are fitted with a head frame, meantime CT and MR scans are
performed to determine treatment  planning.  After  the acquisition of  these informations,
patients  are  positioned  on  treatment  couch  and  the  linear  accelerator  directs  arcs  of
radioactive photon beams to tumor. The pattern of the arc is computer - matched to the
tumor shape using specific multileaf collimators. The CT/MR data of patients are sent to
a computerized treatment platform. Through, this platform CT/MR images are fused using
an image fusion software and the CTV is defined and contoured manually by clinicians
and physicists.  In  our  department,  an integration of  images  with metabolic  information
such as single photon emission computed tomography (SPECT) has also been used. This
permits sometimes to obtain a more accurate tumor visualization. The fusion of images is
obtained by a commercial software package (Ergo- 3Dline®). Obtained the CTV, normal‐
ly, a margin over these countered borders must be defined to take into account the possible
microscopic extension of the tumour not evidenced on the CT/MR scans. These margins
are generally countered 10-30 mm around the CTV obtaining the planned target volume
(PTV).  After  PTV determination a  new contour is  done ensuring PTV coverage by 95%
isodose  line  with  the  aim  for  obtaining  a  uniform  dose  homogeneity.  Treatment  is
performed using a Varian Clinac 2100, 6mv. The median dose used for GBM and anaplas‐
tic astrocytomas treated with HT were of 36.87±17.75 Gy versus 39.2 ± 15.57 Gy for patients
treated  with  CFRT+TMZ  alone.  The  radiotherapeutic  volume  were  54.04  ±  22.53  mm3
versus 85.12 ± 50.37 mm3 respectively.
1.2. Capacitive hyperthermia
For treating our patients we used a device (Synchrotherm) developed by Duer ®, Vigeva‐
no, Italy. This device consists of the following components:  1) a Radiofrequency genera‐
tor (13.56 Mhz) 2) a pair of mobile plates or electrodes with independent superficial cooling
system,  3)  a  heat  exchanger,  4)  a  computerized control  console.  The thermal  profiles  to
obtain a probable deposition of the energy were obtained by heating patterns produced in
a static phantoms. A cylindrical phantom made of 4% agar gel plus 02% NaCl was made
and the various isotherms were monitored and reconstructed through computerizations of
images obtained by a special film sensible to temperature. A flexible vinyl sheet, forming
a space filled with 0.4% NaCl solution, covered the surfaces of the electrodes. The saline
solution  circulated  between  the  electrode  and  the  heat  exchangers.  Differently  to  other
cooling  system,  the  two  electrodes  were  independently  controlled  and  were  simply
adaptable to the contour of the brain patients, thanks to their flexibility These plates are
coupled  to  opposite  side  of  the  patient  ‘s  brain  and  kept  in  place  thanks  to  a  girdle
permitting a better contact over the irregularity of the skull contour. Capacitive hyperther‐
mia treatment were given to the patients 30 ‘ after the CFRT; during the HT session 500cc
of mannitol at 19%, plus 4-8 mg of desamethazone were infused. HT treatments lasted for
all patients 1 hour, and for five days consecutively. Some of these patients received more
than one HT treatment/month (median 3 maximum 5 HT treatments).
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2. TMZ administration
TMZ was administered orally 200mg/m2 /day on day one to five, after written informed
consent. A full blood examination was performed before each new cycle. The treatment cycles
were repeated every 28 days. The patients fasted 4 hours before TMZ use, and were submitted
to conformal radiotherapy (CFRT), following our standards supplementation with omega-3
fatty acids and silymarin for preventing radionecrosis.
3. Rationale for using liposomal doxorubicin
Temozolomide is an imido-tetrazine readily absorbed orally and able to cross the Blood brain
barrier. TMZ has demonstrated activity against Glioblastoma, astrocytoma of various degree
and brain metastases [3, 15]. Although TMZ has become the drug of choice in association with
radiotherapy for Glioblastoma, many Glioblastoma develop resistance to the drug and become
incurable. The reasons for this resistance is at the moment not completely understood and
seems linked to the presence of certain subpopulations of cancer- stem cells inside the tumor
mass [32]. This possible resistance has forced our group to look for other drugs active on GBM.
We have chosed liposomal doxorubicin for various reasons that we will be describe here.
Liposomal  doxorubicin  (Caelyx®),  is  a  formulation  of  hydrochloride  doxorubicin  wrap‐
ped by a film composed by phospholipids and polymers of methoxypolyethylene (mPEG)
embedded in the lipid surface [33]. This association determines favorable pharmacokinet‐
ic  profile  characterised  by  an  extended  circulation  time,  a  reduced  volume of  distribu‐
tion,  thereby  promoting  an  increased  tumour  uptake  [34,  35].  Tumor  abnormal
microcirculation and permeability is responsible for the increased uptake and retention of
liposomal  drugs,  see  Maeda  [36].  This  phenomenon  is  greatly  increased  by  Hyperther‐
mia, as demonstrated by Ponce and Dvorak [37, 38].  Dvorak was one of the first to use
the  combination  of  Caelyx® and hyperthermia  on hepatocarcinoma and after  his  study
reported  that  the  combination  of  hyperthermia  and  doxorubicin  itself  may  be  supra-
additive, resulting in enhanced antitumor efficacy in the heated region and in decrease of
toxicity  [38].  Caelyx®  has  been  investigated  by  Koukoukaris  in  glioblastoma  and  in
metastatic brain tumours [39]. These authors in agreement with Chua and Lesniak group
concluded that  liposomal  doxorubicin  selectively  overcome the  blood brain  barrier  and
accumulate 13-19 times higher in the Glioblastoma [40,  41].  Furthermore,  Chua [40]  has
demonstated  the  possibility  of  using  Caelyx®  in  association  with  temozolomide  in
recurrent  Glioblastoma.  Liposomal doxorubicin was associated with disease stabilization
and  a  modest  haematologic  toxicity.  These  studies  have  convinced  our  group  to  use
pegylated doxorubicin in a recurrent case of GBM. The case is here briefly described.
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4. Case of patient treated with Caelyx
The patient (right handed man) was first surgically treated (Dec 2005) for left posterior parietal
Glioblastoma then the patient underwent RT (45 Gy CFRT in 18 fractions followed by a boost
CFRT to reduced target of 20 Gy in 4 fractions) and started and continued Temodar (10 cycles)
until progression (Jan 07) followed by ACNU (2 Cycles) until progression (March 2007) and
then we started LD and Radiofrequency Hyperthermia (HT).
During the first period the cycles were done at 45 days interval then, after a initial good
response and stabilization, the treatment was done at larger interval up to 9 CT+HT (the last
treatment was done in Nov 2007).
The treatment was as follows: 12 mgm2 IV + steroids in glucose solution and assumption of
200 mg of Quercetin in day 1 and one hour of HT at least four hour later. From day 2 to 5 the
patient underwent 4 further consecutive days of HT and quercetin (100 mg before and after
the completion of treatment).
HT was delivered by means of a 13.56 MHz radiofrequency capacitive device (Synchrotherm
Duer) via two opposite plates at the maximum tolerated power for at least one hour for five
consecutive days.
4.1. Statistical analysis
Survival curves were calculated according to Kaplan-Meier method, Starting on the first day
of HT. Survival was compared using the log-rank test and the K-test. Significance was posed
as p ≤ 0.05 [11].
4.2. Results
As it is possible to see comparing table 1 and table 2 there is no statistical difference between
the two groups regarding age, gy administered and volume of tumour treated. The difference
on survival curves (see Fig. 1) using the log-rank test and the K-test are important and more
than the 50% of patients treated with CFRT+HT+TMZ are alive at 26 months. We can object
than the comparison of the two groups is not completely homogeneous. In fact, the group in
table 2 treated with TMZ + CFRT are only GBM, on the contrary in table 1 there is the presence
of Astrocytoma of II degree. At a second look at table 1, an important observation emerges
however, the GBM group has a long survival that is sometimes 3 times that of table 2, see pts
1, 3 table 2 and pts 3,7,10 of table1. It seems clear that HT adds something regarding survival
and no side effects have been reported by patients. The patient treated with Caelyx® after
surgery Dec 2005, had progression of the disease. He received CFRT in February 2006 and 10
cycles of Temodal. The patient on March 2009 shows progression and possible resistance to
Temodal, we decided to treat the patient with 11 cycles of Caelyx + HT. The patient situation
is illustrated in Fig 1( progression of disease after 10 cycle of Temodal, 2006) and Fig 2 after 11
cycles of Caelyx + HT (2009). The decrease of volume is evident. The patient is still alive and
in treatment with a dose of 80 mg of Talidomide taken orally at evening, as a single dose.
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Pts Gender Age RTV(cm3) Gy D / A Ms Survival
1 F 30 31.6 36.4 D 30
2 M 52 65.4 20 D 13
3 F 64 108 40.5 D 37
4 M 22 56.8 25 D 9
5 M 69 76.9 45.6 D 15
6 M 57 64.1 70 D 1
7 F 61 175 18 D 2
8 F 65 64.5 35 D 10
9 F 47 19.8 54 D 25
10 M 66 136.9 45.5 D 4
11 M 50 226 42 D 13
12 F 45 19.9 54 D 19
13 M 67 67.9 20.4 D 26
14 M 65 119 20 D 14
15 F 22 45 45 D 5
15 7F- 8M 52.13±16.177 85.12±50.37 39.2±15.57 15 D 14.87±10.7
Pts: Patients; RTV: radiotherapeutic volume; Gy: Gray; D: dead, A: Alive; Ms: months
Table 2. Characteristics of Patients with GBM treated with CFRT + TMZ
Figure 1. Survival curve of patients treated with HT + CFRT + Temodal, compared with CFRT + Temodal
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 (a) 
(b) 
Figure 2. a. Patient with recurrent and drug resistance before Hyperthermia and Caelyx treatmen. b. Decrease of GBM
volume after Hyperthermia and Caelyx treatment
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5. Conclusions
Our study, is in agreement with the previous studies on HT [29], and show that the association
with themozolomide is feasible and that this triple treatment (Chemotherapy, Conformal
Radiotherapy and hyperthermia) represents a promising new approach to the treatment of
glioblastomas. In this initial work we have not analyzed patients treated with hyperthermia
without TMZ, so we cannot understand if the increase in life survival must be ascribed simply
to HT or to the combination with temozolamide. The quantity of patients is limited but we are
encouraged to use external capacitive HT in association with the standard therapy of our
institution. In a near future, we hope to be able to distinguish the effects of the two therapies.
We hope also to analyze the compliance of the patients to hyperthermia and to be able to study
the side effects of HT on brain. We want to point out that most of works done on brain and
hyperthermia regards studies with interstitial HT [29]. Interstitial HT represents to our opinion
a limit to a larger use of this technique in association with CFRT and chemotherapy, whereas
capacitive HT show a simpler use and seems to be well tolerated by patients.
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